Guest: Jeffrey Low, Principal @ Novo Holdings Jeffrey Low joined Growth Investments in 2020 as a Principal. Jeffrey focuses on investments in the life sciences and technology and is based in our San Francisco office. He joins us from Andreessen Horowitz where he established the firm’s therapeutics practice and actively invested at the intersection of life sciences, healthcare, and technology. Jeffrey holds an MD from Yale School of Medicine, an MBA from Harvard Business School, and an AB in Molecular and Cellular Biology from Harvard University. Host: Chris Ghadban _______________________ Join BIOS Community 🎉 Become a member, continue the conversation, connect with like-minded Life Science innovators, access exclusive resources, & invite-only events… Apply to Join —https://docs.google.com/forms/d/e/1FAIpQLSft6P6HhSwMDJbFEW9j7HU6vZwjza9PRNN5ZdSGENj7HwhL7A/viewform For More Interesting Content 💭 🦾 Website: https://www.bios.community/ 🧬 Podcast: https://open.spotify.com/show/2HmcPq9k8fYpn60F3hw6Ra?si=uH9wk7SiRAiVUeP1dmwi7Q 🧪 Medium: https://medium.com/bios-community 🩺 Twitter: https://twitter.com/bios_community 🦠 LinkedIn: https://www.linkedin.com/company/bios-community 🧠 Substack: https://bioscommunity.substack.com _______________________ BIOS: Nucleus of Life Science Innovation 🚀 Alix Ventures: Driving Patient Impact - Supporting Early Stage Startups Engineering Biology to Create Radical Advances in Human Health🌟

Join us for a discussion on investments year-to-date for health-tech and life science companies and the impact of M&A deals from 2019. How have investment strategies and priorities changed? How do they work with startups/growth stage companies? How are strategic investors changing the investment landscape? What have they learned from investment missteps and successes? Moderator: Peter Micca, Partner, Deloitte & Touche LLP Speakers: Julie Grant, General Partner, Canaan Jeffrey Low, M.D., Principal, Novo Growth Christopher McFadden, Managing Director, KKR Credit

What challenges do first-time founders or tech founders encounter when building companies in the bio space, and how does it differ from traditional tech companies? In this hallway-style conversation, a16z bio team partners -- including general partners Jorge Conde and Vijay Pande, with Jeff Low -- discuss the mindset shifts involved with building bio (and especially therapeutics) companies. They cover everything from different paths to market and different partnerships (including pharma), to different timelines and milestones for validating the product and business itself. And finally, how do we get to common language that bridges the worlds of tech and bio? *** The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments and certain publicly traded cryptocurrencies/ digital assets for which the issuer has not provided permission for a16z to disclose publicly) is available at https://a16z.com/investments/. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.

No matter how grand a vision for a particular industry, disruption in practice is hard. This is especially true in industries like healthcare, which have long been resistant to software-driven change. But sometimes you can innovate within the bounds of the industry, using those very constraints to move it forward -- whether it’s understanding and working with the early adopters in healthcare to focusing on the bottomline. This conversation -- recorded at our recent a16z Summit in November 2017 -- between co-founder and CEO of Omada Health, Sean Duffy and CEO of Accolade, Rajeev Singh (moderated by a16z bio fund partner Jeff Low), considers how such innovation affects go-to-market strategies and pricing to measuring savings and the entire ecosystem of healthcare spend. As this generation of digital health tech companies begin to change the healthcare business -- and scale -- what effect are they having on the rising cost of heathcare overall, and the bottom line?